In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: A comparison with human liver microsomes

Biochemical Pharmacology

Volumn 76, Issue 6, 2008, Pages 784-795

  Quintieri, Luigi ^a   Fantin, Marianna ^a   Palatini, Pietro ^a   De Martin, Sara ^a   Rosato, Antonio ^a,b   Caruso, Michele ^c   Geroni, Cristina ^c   Floreani, Maura ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Nerviano Medical Sciences Srl ^*  (Italy)

Author keywords

CYP3A enzymes; Liver microsomes; Nemorubicin oxidative metabolism; PNU 159682; Sex and species related differences

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 3A4; DRUG METABOLITE; NEMORUBICIN; PNU 159682; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; SPECIES COMPARISON; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DOGS; DOXORUBICIN; FEMALE; HUMANS; MALE; MICE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 50549100382     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.07.003     Document Type: Article

References (45)

1. Grandi M., Pezzoni G., Ballinari D., Capolongo L., Suarato A., Bargiotti A., et al. Novel anthracycline analogues. Cancer Treat Rev 17 (1990) 133-138
2. Ripamonti M., Pezzoni G., Pesenti E., Pastori A., Farao M., Bargiotti A., et al. In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Br J Cancer 65 (1992) 703-707
3. Danesi R., Agen C., Grandi M., Nardini V., Bevilacqua G., and Del Tacca M. 3′-Deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer 29A (1993) 1560-1565
4. Mazué G., Iatropoulos M., Imondi A., Castellino S., Brughera M., Podestà A., et al. Anthracyclines: a review of general and special toxicity studies. Int J Oncol 7 (1995) 713-726
5. Mariani M., Capolongo L., Suarato A., Bargiotti A., Mongelli N., Grandi M., et al. Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR. Invest New Drugs 12 (1994) 93-97
6. Bakker M., Renes J., Groenhuijzen A., Visser P., Timmer-Bosscha H., Müller M., et al. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. Int J Cancer 73 (1997) 362-366
7. Sessa C., Valota O., and Geroni C. Ongoing phase I and II studies of novel anthracyclines. Cardiovasc Toxicol 7 (2007) 75-79
8. Ghielmini M., Colli E., Bosshard G., Pennella G., Geroni C., Torri V., et al. Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Cancer Chemother Pharmacol 42 (1998) 235-240
9. Lau D.H., Duran G.E., Lewis A.D., and Sikic B.I. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer 70 (1994) 79-84
10. Quintieri L., Rosato A., Napoli E., Sola F., Geroni G., Floreani M., et al. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Res 60 (2000) 3232-3238
11. Baldwin A., Huang Z., Jounaidi Y., and Waxman D.J. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys 409 (2003) 197-206
12. Lu H., and Waxman D.J. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism. Mol Pharmacol 67 (2005) 212-219
13. Quintieri L., Geroni C., Fantin M., Battaglia R., Rosato A., Speed W., et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 11 (2005) 1608-1617
14. Vasey P.A., Bissett D., Strolin-Benedetti M., Poggesi I., Breda M., Adams L., et al. Phase I clinical and pharmacokinetic study of 3-deamino-3-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762). Cancer Res 55 (1995) 2090-2096
15. Baldwin S.J., Bloomer J.C., Smith G.J., Ayrton A.D., Clarke S.E., and Chenery R.J. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25 (1995) 261-270
16. Newton D.J., Wang R.W., and Lu A.Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23 (1995) 154-158
17. Lu P., Singh S.B., Carr B.A., Fang Y., Xiang C.D., Rushmore T.H., et al. Selective inhibition of dog hepatic CYP2B11 and CYP3A12. J Pharmacol Exp Ther 313 (2005) 518-528
18. Delaforge M., Jaouen M., and Mansuy D. The cytochrome P-450 metabolite complex derived from troleandomycin: properties in vitro and stability in vivo. Chem Biol Interact 51 (1984) 371-376
19. Ciaccio P.J., and Halpert J.R. Characterization of a phenobarbital-inducible dog liver cytochrome P450 structurally related to rat and human enzymes of the P450IIIA (steroid-inducible) gene subfamily. Arch Biochem Biophys 271 (1989) 284-299
20. Chang T.K., Gonzalez F.J., and Waxman D.J. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311 (1994) 437-442
21. Yuan R., Madani S., Wei X.X., Reynolds K., and Huang S.M. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30 (2002) 1311-1319
22. Perloff M.D., von Moltke L.L., Court M.H., Kotegawa T., Shader R.I., and Greenblatt D.J. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292 (2000) 618-628
23. Kobayashi K., Urashima K., Shimada N., and Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 63 (2002) 889-896
24. Kotegawa T., Laurijssens B.E., Von Moltke L.L., Cotreau M.M., Perloff M.D., Venkatakrishnan K., et al. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302 (2002) 1228-1237
25. Watkins P.B., Murray S.A., Winkelman L.G., Heuman D.M., Wrighton S.A., and Guzelian P.S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 83 (1989) 688-697
26. Lown K., Kolars J., Turgeon K., Merion R., Wrighton S.A., and Watkins P.B. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 51 (1992) 229-238
27. Born S.L., Fraser D.J., Harlow G.R., and Halpert J.R. Escherichia coli expression and substrate specificities of canine cytochrome P450 3A12 and rabbit cytochrome P450 3A6. J Pharmacol Exp Ther 278 (1996) 957-963
28. Kerry N.L., Somogyi A.A., Bochner F., and Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 38 (1994) 243-248
29. Di Marco A., Yao D., and Laufer R. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur J Biochem 270 (2003) 3768-3777
30. Shou M., Norcross R., Sandig G., Lu P., Li Y., Lin Y., et al. Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes P450. Drug Metab Dispos 31 (2003) 1161-1169
31. Quintieri L., Palatini P., Nassi A., Ruzza P., and Floreani M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem Pharmacol 75 (2008) 1426-1437
32. Segel J.H. Enzyme Kinetics (1975), John Wiley & Sons
33. Venkatakrishnan K., Von Moltke L.L., and Greenblatt D.J. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41 (2001) 1149-1179
34. Graham R.A., Downey A., Mudra D., Krueger L., Carroll K., Chengelis C., et al. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab Dispos 30 (2002) 1206-1213
35. Corcos L. Phenobarbital and dexamethasone induce expression of cytochrome P-450 genes from subfamilies IIB, IIC, and IIIA in mouse liver. Drug Metab Dispos 20 (1992) 797-801
36. Murayama N., Shimada M., Yamazoe Y., Sogawa K., Nakayama K., Fujii-Kuriyama Y., et al. Distinct effects of phenobarbital and its N-methylated derivative on liver cytochrome P4540 induction. Arch Biochem Biophys 328 (1996) 184-192
37. Ono S., Hatanaka T., Hotta H., Satoh T., Gonzalez F.J., and Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26 (1996) 681-693
38. Hickman D., Wang J.P., Wang Y., and Unadkat J.D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26 (1998) 207-215
39. Bogaards J.J., Bertrand M., Jackson P., Oudshoorn M.J., Weaver R.J., van Bladeren P.J., et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30 (2000) 1131-1152
40. Guengerich F.P., and Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4 (1991) 391-407
41. Lu A.Y., Wang R.W., and Lin J.H. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31 (2003) 345-350
42. Kawai M., Bandiera S.M., Chang T.K., and Bellward G.D. Growth hormone regulation and developmental expression of rat hepatic CYP3A18, CYP3A9, and CYP3A2. Biochem Pharmacol 59 (2000) 1277-1287
43. Cooper K.O., Reik L.M., Jayyosi Z., Bandiera S., Kelley M., Ryan D.E., et al. Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Arch Biochem Biophys 301 (1993) 345-354
44. Mahnke A., Strotkamp D., Roos P.H., Hanstein W.G., Chabot G.G., and Nef P. Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch Biochem Biophys 337 (1997) 62-68
45. Mugford C.A., and Kedderis G.L. Sex-dependent metabolism of xenobiotics. Drug Metab Rev 30 (1998) 441-498